Nov 26 (Reuters) - Cognition Therapeutics Inc CGTX.O:
COGNITION THERAPEUTICS ANNOUNCES ALL PARTICIPANTS HAVE COMPLETED THEIR FINAL VISITS IN THE PHASE 2 SHIMMER STUDY OF CT1812 IN DEMENTIA WITH LEWY BODIES
COGNITION THERAPEUTICS INC -TOPLINE RESULTS IN SECOND DEMENTIA INDICATION EXPECTED TO BE REPORTED IN DECEMBER 2024
Source text: ID:nGNX7N8MYJ
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))